MBX Biosciences, Inc. (MBX)
66.76
-1.86
(-2.71%)
USD |
NASDAQ |
Aug 26, 16:00
66.50
-0.26
(-0.39%)
After-Hours: 05:43
MBX Biosciences Shareholders Equity (Quarterly) : 409.54M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 409.54M |
| March 31, 2026 | 437.76M |
| December 31, 2025 | 369.22M |
| September 30, 2025 | 387.54M |
| June 30, 2025 | 219.24M |
| March 31, 2025 | 235.42M |
| Date | Value |
|---|---|
| December 31, 2024 | 257.44M |
| September 30, 2024 | 271.37M |
| June 30, 2024 | 54.47M |
| March 31, 2024 | 69.31M |
| December 31, 2023 | 79.89M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Amylyx Pharmaceuticals, Inc. | 239.17M |
| ANI Pharmaceuticals, Inc. | 597.21M |
| Corcept Therapeutics, Inc. | 705.78M |
| Veru, Inc. | 28.38M |
| Johnson & Johnson | 84.97B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 435.91M |
| Total Liabilities (Quarterly) | 26.37M |
| Debt to Equity Ratio | 0.0082 |
| Current Ratio | 18.08 |
| Net Debt Paydown Yield | -0.02% |